Antidepressants Linked To Stroke Risk

A study published in Neurology revealed that individuals who use common antidepressants called selective serotonin reuptake inhibitors (SSRIs) could have a heightened risk of suffering a stroke.

A team of investigators looked at past studies to analyze the connection between antidepressant use and stroke. Evidence from 16 studies was pooled, with over 500,000 total participants included. Overall antidepressant users were about 40 to 50 percent more likely to suffer bleeding in or around the brain.

Researchers focused on the popular antidepressants including; Celexa (citalopram), Lexapro (escitalopram), Paxil (paroxetine), Prozac (fluoxetine), Viibryd (vilazodone), and Zoloft (sertraline).

“Overall, these results should not deter anyone from taking an SSRI when it is needed,” explained the study’s author Daniel G. Hackam, a researcher at Western University in London, Ontario in a prepared statement. “In general these drugs are safe, and obviously there are risks to having depression go untreated. But doctors might consider other types of antidepressants for people who already have risk factors for these types of strokes, such as those taking blood thinners, people who have had similar strokes already or those with severe alcohol abuse.”

The researchers noted that approximately 24.6 of the strokes happen among every 100,000 people annually. Use of antidepressants heightens the risk to one extra stroke for every 10,000 people in a year.

One of the limitations noted of the study was that it didn’t factor in the possibility that patients who use SSRIs are “sicker” that individuals who did not take the medications. These factors include habits like smoking and drinking. The study also didn’t take into account chronic disease like diabetes that may plague patients who take SSRIs.

“We can’t infer cause and effect from this,” said Hackam on how the findings of the study do not show direct correlation between antidepressants and bleeding in the brain.

Reuters reported that biological factors could be at play. SSRIs can make it difficult for the platelets, otherwise known as blood cells, to clump and create clots. As a result, there may be a decline in the activity of a person’s platelets.

Even with the results of the study, the researchers believe the medications are still safe

“I think that overall, these medications are quite safe,” Hackam told Reuters Health.

An editorial, compiled by Emer McGratgh and Martin O’Donnell, accompanied the published study in the journal and emphasized the study as “best current evidence of an association between SSRI use and risk of ICH.” They also advised that the uptick in ICH should not stop medical professionals from prescribing SSRIs.

“These findings emphasize the importance of appropriate patient selection and avoidance of inappropriate prescribing, which assumes particular importance in patients at increased risk of ICH,” wrote the authors in the editorial. “SSRIs may be associated with an increased risk of ICH but the absolute risk in populations is low. These findings add to the totality of evidence for efficacy and safety of antidepressants overall and within drug classes, used to inform evidence-based prescribing.”

Antidepressant usage has been linked with a number of adverse side effects, including but not limited to, stomach bleeding, high blood pressure, birth defects, and even autism.

You May Also Like


  • This field is for validation purposes and should be left unchanged.

, , , , ,

No comments yet.

Leave a Reply

  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.